Abstract
T-cells are central players in the immune response against both pathogens and cancer. Their specificity is solely dictated by the T-cell receptor (TCR) they clonally express. As such, the genetic modification ofT lymphocytes using pathogen- or cancer-specificTCRs represents an appealing strategy to generate a desired immune response from peripheral blood lymphocytes. Moreover, notable objective clinical responses were observed in terminally ill cancer patients treated with TCR-gene modified cells in several clinical trials conducted recently. Nevertheless, several key aspects of this approach are the object of intensive research aimed at improving the reliability and efficacy of this strategy. Herein, we will survey recent studies in the field of TCR-gene transfer dealing with the improvement of this approach and its application for the treatment of malignant, autoimmune, and infectious diseases.
Original language | English |
---|---|
Article number | Article 186 |
Journal | Frontiers in Immunology |
Volume | 3 |
Issue number | JUL |
DOIs | |
State | Published - 2012 |
Bibliographical note
This work was supported by the Israel Science Foundation(773/08) and by the Marie-Curie International Reintegration
Grant (224851) from the European Community.
Funding
Funders | Funder number |
---|---|
Seventh Framework Programme | 224851 |
Keywords
- Autoimmunity
- Cancer
- Immunotherapy
- Infectious diseases
- T-cell receptor
- T-cells
- TCR-gene transfer